Clinical trials: Coronavirus Infections
COVID-19
Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics of AT-527 versus a placebo in participants with mild or moderate coronavirus disease (COVID-19) who are not hospitalized.
- Trial name
- NCT04709835
- Testing
- AT-527
- Where
- 12 sites in Canada, Greece and 4 more
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
Covid19, SARS-CoV Infection
A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections
Prospective, observational, exploratory study exploring the relationship between passively-collected data from wearable activity devices and SARS-CoV-2 infection
- Trial name
- NCT04623138
- Where
- United States
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- Evidation Health
Convalescence, Corona Virus Infection
Convalescent Plasma Therapy in Patients With COVID-19
Scientists and medical workers all around the world were running out of time to manage COVID-19. Several studies have been done to understand the disease and ultimately to find possible treatment.
- Conditions
- Convalescence, Corona Virus Infection, Plaque
- Trial name
- NCT04407208
- Testing
- Convalescent plasma
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Biofarma
COVID-19
A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients…
- Trial name
- NCT04628143
- Testing
- Nafamostat Mesilate
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Chong Kun Dang Pharmaceutical
COVID-19, Asymptomatic COVID-19
A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test
To determine the accuracy of Proof Diagnostics COVID-19 Test in the intended, symptomatic and suspected/at-risk asymptomatic population and point-of-care use as compared to a standard molecular comparator, Quidel Lyra SARS-CoV-2…
- Trial name
- NCT05331976
- Testing
- Proof Lab Test System
- Where
- 3 sites in United States
- Volunteers
- 276 people
- Sponsor
- Proof Diagnostics
COVID19
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19
This study is a Phase 1, open label, non-randomized, two-arm interventional clinical trial to evaluate the safety and efficacy of Virazole® in hospitalized adult patients who have tested positive for COVID-19 and, as a result…
- Trial name
- NCT04551768
- Testing
- 50 mg/mL Virazole, 100 mg/mL Virazole
- Where
- 4 sites in Greece, Mexico
- Volunteers
- 51 people
- Sponsor
- Bausch Health Americas, Inc.
COVID-19
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
A Phase 1 study to evaluate safety, tolerability, and immunogenicity of SARS-CoV-2 variant mRNA vaccines which are used to prevent COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT05434585
- Testing
- ABO1009-DP, ABO-CoV.617.2
- Where
- 2 sites in Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Covid19
Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19
This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Novaferon, in hospitalized adult patients diagnosed with COVID-19.
- Trial name
- NOVATION-1 (NCT04669015)
- Testing
- Novaferon
- Where
- 88 sites in Argentina, Brazil and 10 more
- Volunteers
- 914 people
- Sponsor
- Genova Inc.
COVID-19
Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
The goal of this clinical study is to test how well the study drug, obeldesivir (GS-5245), works and how safe it is in treating coronavirus disease 2019 (COVID-19) in participants that have a higher risk of getting a serious…
- Trial name
- BIRCH (NCT05603143)
- Testing
- Obeldesivir
- Where
- 81 sites in Brazil, Bulgaria and 16 more
- Volunteers
- 468 people
- Sponsor
- Gilead Sciences
COVID-19
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine
This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing…
- Trial name
- C4591068 (NCT06703190)
- Testing
- Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
COVID-19
SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19
In this first-in-humans dose escalation study, SA55 will be evaluated for safety, tolerability, and pharmacokinetics. The study is intended to enable future studies of SA55-injection's efficacy in preventing and treating COVID-19.
- Trial name
- NCT06050460
- Testing
- SA55 Injection
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Covid19
Evaluating the Impact of EnteraGam In People With COVID-19
Background: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged as a potentially life-threatening disease in Wuhan, China, at the end of 2019.
- Trial name
- PICNIC (NCT04682041)
- Testing
- Bovine Plasma-Derived Immunoglobulin Concentrate, Standard of care
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Entera Health, Inc
SARS CoV 2 Infection
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in…
- Trial name
- NCT05303402
- Testing
- PHH-1V
- Where
- 6 sites in Spain, Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Hipra Scientific, S.L.U
Autoimmune Diseases, Cardiovascular Disorders
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions.
- Conditions
- Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease
- Trial name
- NCT04684602
- Testing
- PrimePro™/ PrimeMSK™
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Thomas Advanced Medical LLC
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI US (NCT04380688)
- Testing
- Acalabrutinib
- Where
- 31 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Healthy
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19.
- Trial name
- NCT05580003
- Testing
- PF-07817883, Midazolam, Moxifloxacin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID19
Clinical Trial to Evaluate the Efficacy of Food Supplement Manremyc® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers
The purpose of this study is to assess the efficacy of Manremyc® food supplement for reduce the incidence of SARS-CoV-2 infection in a high risk population, as healthcare workers.
- Trial name
- NCT04452773
- Testing
- Manremyc
- Where
- 5 sites in Spain
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Reig Jofre Group
SARS-CoV-2
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.
- Trial name
- NCT04958954
- Where
- United States
- Volunteers
- 50,000,000 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2 Infection
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
This is a clinical study to investigate the safety, tolerability and immunogenicity of a VLA2001 booster vaccination in participants aged 18 years and older. In total approximately 275 participants are planned to be enrolled.
- Trial name
- NCT05364242
- Testing
- VLA2001
- Where
- 4 sites in Netherlands, New Zealand
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.